Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial

Haematologica

Volumn 101, Issue 9, 2016, Pages 1065-1073

  Al Ali, Haifa Kathrin ^a   Griesshammer, Martin ^b   le Coutre, Philipp ^c   Waller, Cornelius F ^d   Liberati, Anna Marina ^e   Schafhausen, Philippe ^f   Tavares, Renato ^g   Giraldo, Pilar ^h   Foltz, Lynda ⁱ   Raanani, Pia ^j   Gupta, Vikas ^k   Tannir, Bayane ^l   Ronco, Julian Perez ^l   Ghosh, Jagannath ^l   Martino, Bruno ^m   Vannucchi, Alessandro M ⁿ  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j RABIN MEDICAL CENTER   (Israel)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l NOVARTIS PHARMA AG   (Switzerland)

^m BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; RUXOLITINIB; BIOLOGICAL MARKER; HEMOGLOBIN; JANUS KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CYSTITIS; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FATIGUE IMPACT SCALE; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HERPES ZOSTER; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIMARY MYELOFIBROSIS; RETREATMENT; SPLEEN; THROMBOCYTE COUNT; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; HEMOGLOBINS; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; PHENOTYPE; PLATELET COUNT; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY OF LIFE; RETREATMENT; SPLEEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84986196617     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.143677     Document Type: Article

References (20)

1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMFBP):consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
2. Swerdlow SH, Campo E, Harrison NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. 4th ed. Geneva, Switzerland: World Health Organization; 2008.
3. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes. Blood. 2009;114(5):937-951.
4. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(2): 141-150.
5. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
6. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: Update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233-245.
7. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203.
8. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
9. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
10. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
11. Cervantes F, Kiladjian JJ, Niederwieser D, et al. Long-term efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis. Blood. 2012;120(21):801.
12. Mead AJ, Milojkovic D, Knapper S, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and highrisk myelofibrosis: Results of the UK ROBUST trial. Br J Haematol. 2015;170(1):29-39.
13. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
14. McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An openlabel, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.
15. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503.
16. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
17. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
18. Carter GC, Liepa AM, Zimmermann AH, Morschhauser F. Validation of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) in patients with relapsed/refractory mantle cell lymphoma. Blood 2008;112(11):2376
19. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution- based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547-561.
20. Davis KL, Cote I, Kaye JA, et al. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015;2015;848473.